Acute Myeloid Leukaemia Clinical Trials

22 recruiting

Acute Myeloid Leukaemia Trials at a Glance

27 actively recruiting trials for acute myeloid leukaemia are listed on ClinicalTrialsFinder across 6 cities in 23 countries. The largest study group is Phase 2 with 16 trials, with the heaviest enrollment activity in Hangzhou, Edinburgh, and Bologna. Lead sponsors running acute myeloid leukaemia studies include First Affiliated Hospital of Zhejiang University, AstraZeneca, and Ascentage Pharma Group Inc..

Browse acute myeloid leukaemia trials by phase

Treatments under study

About Acute Myeloid Leukaemia Clinical Trials

Looking for clinical trials for Acute Myeloid Leukaemia? There are currently 22 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Acute Myeloid Leukaemia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Acute Myeloid Leukaemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 27 trials

Recruiting
Phase 1Phase 2

Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

Myeloid MalignancyRelapsed/Refractory Acute Myeloid Leukaemia
Ascentage Pharma Group Inc.682 enrolled12 locationsNCT04501120
Recruiting
Phase 2Phase 3

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

Acute Myeloid Leukaemia (AML)
Moleculin Biotech, Inc.312 enrolled25 locationsNCT06788756
Recruiting
Phase 1Phase 2

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

Acute Lymphoblastic LeukaemiaAcute Myeloid Leukaemia
AstraZeneca84 enrolled30 locationsNCT07155226
Recruiting

Leukemia Adapted Protocol

Acute Myeloid Leukaemia
Baylor College of Medicine30 enrolled1 locationNCT06928909
Recruiting
Phase 1

Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia

Refractory/Relapsed Acute Myeloid Leukaemia
Beijing GoBroad Hospital27 enrolled4 locationsNCT06326021
Recruiting

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

Acute Myeloid Leukaemia (AML)Follicular Lymphoma ( FL)
Tempus AI550 enrolled5 locationsNCT07154823
Recruiting
Phase 1Phase 2

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

LeukemiaBlood CancersBlood Cancer+1 more
Jacqueline Garcia, MD31 enrolled2 locationsNCT07148180
Recruiting
Phase 1

Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics

Myelodysplastic Syndrome (MDS)Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)Acute Myeloid Leukaemia (AML)
medac GmbH36 enrolled4 locationsNCT05534620
Recruiting
Not Applicable

Maintenance Venetoclax in AML Fit Patients

Acute Myeloid Leukaemia (AML)
Sohag University80 enrolled2 locationsNCT07244367
Recruiting
Phase 2

Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML

Myeloid MalignancyRelapsed/Refractory Acute Myeloid Leukaemia
First Affiliated Hospital of Zhejiang University72 enrolled1 locationNCT06621212
Recruiting
Not Applicable

Feasibility and Safety of Home Blood Count Measurement and Transfusions in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukaemia (AML)
Rigshospitalet, Denmark15 enrolled1 locationNCT07062250
Recruiting
Phase 1Phase 2

Clinical Study of U32 in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukaemia
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd20 enrolled1 locationNCT07036250
Recruiting
Phase 2

Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation

Myelodysplastic SyndromeAcute Myeloid LeukaemiaRecipients of Allogeneic Stem Cell Transplantation+1 more
Vastra Gotaland Region100 enrolled5 locationsNCT06793410
Recruiting
Phase 2

Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation

MDS (Myelodysplastic Syndrome)Acute Myeloid LeukaemiaMPN (Myeloproliferative Neoplasms)
Istituto Clinico Humanitas42 enrolled2 locationsNCT06892223
Recruiting
Not Applicable

Safely Delivered Targeted High-dose Irradiation Followed by Adoptive Immunotherapy with Regulatory and Conventional T Cells to Increase Potency of Hematopoietic Stem Cell Transplantation in High-risk Acute Leukemia

Acute Lymphoblastic Leukemia ALLAcute Myeloid Leukaemia (AML)High Risk Leukaemia+1 more
University Of Perugia51 enrolled1 locationNCT06845592
Recruiting
Phase 2

Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML

Myeloid MalignancyRelapsed/Refractory Acute Myeloid Leukaemia
First Affiliated Hospital of Zhejiang University34 enrolled1 locationNCT06434662
Recruiting
Phase 3

MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)

Acute Myeloid Leukaemia
Zhongnan Hospital154 enrolled11 locationsNCT06345365
Recruiting
Phase 1

An Exploratory Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of ZE63-0302 in Healthy Volunteers

Acute Myeloid Leukaemia (AML)
Eilean Therapeutics AU Pty Ltd (A subsidiary of Eilean Therapeutics LLC)88 enrolled1 locationACTRN12624000180516
Recruiting
Phase 2

AMLM26/T1 INTERCEPT: A multi-arm trial for patients with acute myeloid leukaemia investigating new treatments which target early relapse and changes in disease characteristics - Gilteritinib+ Venetoclax

Acute Myeloid Leukaemia
Australasian Leukaemia and Lymphoma Group45 enrolled16 locationsACTRN12624000082505
Recruiting
Phase 2

A multi-centre phase II, Australian and New Zealand, exploratory study of amendments to conditioning regimens in haplo-identical stem cell transplantation

transformed AML/ MDSMyeloproliferative DisordersHodgkin's Disease+4 more
St Vincent's Hospital, Sydney127 enrolled10 locationsACTRN12622001232729